Loading clinical trials...
Loading clinical trials...
A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors
Conditions
Interventions
AZD2281
AZD5363
+2 more
Locations
4
United States
Yale Cancer Center
New Haven, Connecticut, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Start Date
November 1, 2015
Primary Completion Date
November 18, 2019
Completion Date
November 18, 2019
Last Updated
December 28, 2022
NCT05372640
NCT06498635
NCT04550494
NCT04235764
NCT06066138
NCT07061964
Lead Sponsor
Joseph Paul Eder
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions